GPS Stock Recent News
GPS LATEST HEADLINES
Note: Gap's FY'23 ended on February 3, 2024.
- GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024 - - RPDD Provides Eligibility for GPS to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties – - Recent Valuations for PRVs Remain Attractive (~$100 million/each) – NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to Galinpepimut-S (GPS), an immunotherapeutic targeting Wilms Tumor-1 (WT1), for the treatment of pediatric acute myeloid leukemia (AML). “GPS has already demonstrated promise in clinical settings for AML, and we believe its potential could extend to pediatric patients,?
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to update shareholders on multi-billion dollar asset valuation following this week's $1b+ revenue potential announcement.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The consensus price target hints at a 27.4% upside potential for Gap (GAP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TomTom N.V. stands at a crossroads, leading in HD mapping and autonomous tech but struggling to compete with giants like Google and deliver consistent returns. Despite technological advancements and partnerships, TomTom's stock has declined 45% since 2020, underperforming the S&P 500 and offering no dividends. TomTom's Q2 2024 earnings highlight new product launches and partnerships, but the company faces significant financial and competitive challenges.
INBS announces the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts.
As gold soars to $2,639, the widening gap from the 50-day moving average signals a potential pullback. Discover what's next for gold prices in our full analysis.
As gold soars to $2,639, the widening gap from the 50-day moving average signals a potential pullback. Discover what's next for gold prices in our full analysis.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.